Literature DB >> 3252890

Propranolol for the control of disruptive behavior in senile dementia.

P G Weiler1, D Mungas, C Bernick.   

Abstract

Six patients with senile dementia, exhibiting severe, disruptive behavior were effectively treated with propranolol in doses ranging from 80 mg per day to 560 mg per day. All six patients were given a trial of propranolol after conventional therapy had failed, and in all patients, the agitated behavior significantly improved. There were no adverse side effects requiring the discontinuation of the propranolol, and in all cases, the agitated behavior was controlled without inducing general sedation. Both the nursing home staff and the families were pleased with the therapeutic effects. Propranolol represents a possible alternative way of addressing the severe problem of agitated behavior in senile dementia patients.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3252890     DOI: 10.1177/089198878800100408

Source DB:  PubMed          Journal:  J Geriatr Psychiatry Neurol        ISSN: 0891-9887            Impact factor:   2.680


  5 in total

1.  Adrenergic receptors in Alzheimer's disease brain: selective increases in the cerebella of aggressive patients.

Authors:  A Russo-Neustadt; C W Cotman
Journal:  J Neurosci       Date:  1997-07-15       Impact factor: 6.167

Review 2.  The basis for behavioural disturbances in dementia.

Authors:  M M Esiri
Journal:  J Neurol Neurosurg Psychiatry       Date:  1996-08       Impact factor: 10.154

Review 3.  Adjunctive therapy in patients with Alzheimer's disease. A practical approach.

Authors:  J Corey-Bloom; D Galasko
Journal:  Drugs Aging       Date:  1995-08       Impact factor: 3.923

Review 4.  Optimal management of behavioural disorders associated with dementia.

Authors:  C A Class; L Schneider; M R Farlow
Journal:  Drugs Aging       Date:  1997-02       Impact factor: 4.271

Review 5.  Successful therapies for Alzheimer's disease: why so many in animal models and none in humans?

Authors:  Rafael Franco; Angel Cedazo-Minguez
Journal:  Front Pharmacol       Date:  2014-06-25       Impact factor: 5.810

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.